H1's New AI Suite Aims to Cut Drug Trial Timelines by Weeks

NEW YORK, NY – April 23, 2026 – Health-tech firm H1 today announced the launch of its Site Network Suite, an artificial intelligence-powered platform designed to overhaul the notoriously slow and fragmented process of finding and activating clinical trial sites. The company claims its new solution can reduce feasibility timelines from months to mere weeks, a significant acceleration that could bring new drugs to market faster.

The new suite creates a unified digital ecosystem where pharmaceutical sponsors and research sites can connect, communicate, and exchange data directly. This model stands in stark contrast to the current industry standard, which often involves a convoluted mix of static databases, manual spreadsheets, and endless email chains to identify and qualify sites for participation in new drug studies.

A New Blueprint for Clinical Trial Feasibility

For decades, the process of initiating a clinical trial has been a major bottleneck in drug development. Sponsors seeking to test a new therapy must first identify research sites with the right equipment, expertise, and access to relevant patient populations. This feasibility process is critical but has remained stubbornly manual and inefficient.

H1’s Site Network Suite aims to fundamentally change this paradigm by creating a single, dynamic source of truth. The platform invites research sites to claim and manage their own digital profiles, where they can showcase their capabilities, list their equipment, and detail their experience. When a sponsor initiates a feasibility study, they can distribute digital questionnaires directly through the platform, and sites can respond within the same system.

“For decades, feasibility has been a fragmented, one-off process built on incomplete data and manual workflows,” said Ariel Katz, co-founder and CEO of H1, in the announcement. “With H1’s Site Network, we’re bringing sponsors and sites into one single, connected system where feasibility becomes faster and continuously improves over time.”

The platform’s architecture is built on three core capabilities:

• Protocol-Aware Site Recommendations: The system’s AI analyzes a trial’s protocol to generate a targeted shortlist of sites that have a history of treating the relevant patient populations.
• Centralized Feasibility Management: All communication, including the distribution and collection of feasibility questionnaires, is handled within the H1 platform, eliminating the need for external spreadsheets and emails.
• Structured, Reusable Data: Site responses are normalized and structured, creating a continuously updated dataset that allows sponsors to compare sites side-by-side and reuse the information for future studies.

This shift from static data to a live, interconnected network is at the heart of the company's value proposition. The goal is to create a flywheel effect, where each interaction enriches the platform’s data, making subsequent feasibility studies even faster and more accurate.

The AI Engine Driving Acceleration

The claim of shrinking feasibility timelines from months to weeks hinges on the platform's sophisticated use of artificial intelligence, built upon H1’s foundational ‘Doctor Graph’—a massive, structured database of healthcare professionals and their affiliations. By applying AI to this data, the Site Network Suite automates tasks that once consumed hundreds of hours of manual labor.

Industry data supports the potential for such dramatic efficiency gains. A recent McKinsey study found that one biotech firm improved enrollment rates by 10-20% simply by using AI for better site selection. Other technology providers in the space, such as Veeva and Florence Healthcare, have reported 45-50% reductions in study startup times with their own digital solutions. H1’s approach of integrating connected data has already shown promise, reportedly saving one rare disease sponsor $13 million in startup costs by enabling an early protocol redesign.

However, the increased reliance on data and AI in a highly regulated industry raises immediate questions about security and compliance. With sensitive patient and trial data in play, adherence to regulations like HIPAA in the U.S. and GDPR in Europe is non-negotiable. Industry experts note that AI, when implemented correctly, can enhance security by automating anonymization processes and deploying advanced algorithms to detect and prevent data breaches in real-time. This aligns with new guidelines jointly issued by the FDA and European Medicines Agency (EMA) in early 2026, which call for a risk-based, human-centric, and transparent approach to using AI in drug development.

Navigating a Crowded and Cautious Market

H1 has labeled its suite a “first-of-its-kind” platform, a claim that rests on its specific model of a unified, AI-driven workflow connecting both sponsors and sites. While the assertion has merit, H1 enters a competitive and rapidly evolving market. Established giants like IQVIA and Veeva, as well as agile players like Florence Healthcare and TriNetX, already offer AI-powered tools to optimize site selection and trial management.

The key differentiator for H1 appears to be its emphasis on creating a single, collaborative environment rather than simply providing data analytics to sponsors or workflow tools to sites. Success will depend on its ability to achieve widespread adoption on both sides of the equation.

Overcoming adoption barriers remains a significant challenge in the historically risk-averse pharmaceutical industry. Integrating new platforms with legacy systems, managing the upfront costs, and addressing cultural skepticism toward new technology are common hurdles. For any new platform to succeed, it must demonstrate a clear return on investment and a user experience that simplifies, rather than complicates, daily workflows.

Early feedback from the research community suggests a willingness to embrace change. “We’re participating in H1’s Site Network to better showcase our site’s capabilities to sponsors,” said Gloria Carlbert, Site Director at Bradenton Research Center. “It helps ensure clinical trials are placed at the right sites by giving sponsors a clearer view of what we can support. This is a meaningful step toward better collaboration.”

Bridging Gaps in Research and Representation

Beyond pure efficiency, the platform’s launch carries significant implications for the diversity and accessibility of clinical research. By creating a comprehensive and easily searchable database of research sites, the technology could elevate the visibility of smaller, community-based hospitals and independent clinics that are often overlooked by sponsors in favor of large academic medical centers.

This democratization of access could also be a powerful tool for improving diversity in clinical trial enrollment. Regulators have increasingly stressed the importance of ensuring that trial participants reflect the real-world populations who will ultimately use the new medicines. H1 claims its platform can help sponsors meet these diversity requirements by leveraging data on demographics and social determinants of health (SDOH) to identify sites capable of reaching underrepresented patient groups.

By analyzing real-world data, the AI can pinpoint geographic areas and specific investigators with access to diverse communities, enabling more targeted and inclusive recruitment strategies. This capability addresses a critical need to ensure that life-saving drugs are proven safe and effective for everyone, not just a narrow subset of the population.

Still, the push toward digitization is not without risk. Experts caution of a potential “digital divide,” where research sites lacking the resources or technical infrastructure to participate in such advanced platforms could be left even further behind. Ensuring that the benefits of this technological leap are distributed equitably will be crucial for realizing the full potential of a more connected and efficient clinical trial ecosystem.